20 mar: INDKALDELSE TIL ORDINÆR GENERALFORSAMLING DEN 11. APRIL 2018 KL. ..
20 mar: Møns Bank A/S – fortegningsemission, optagelse til handel og offi..
20-03-2018 14:01:10

Lundbeck held its Annual General Meeting on 20 March 2018 at the company’s registered office

Relateret indhold
18 sep - 
Aktier/åbning: Bavarian og Lundbecks nedtur fortsætter ..
17 sep - 
Mandagens aktier: Bavarian og Lundbeck nederst i småsur..
17 sep - 
Aktier/middag: Defensive papirer tager bunden mens fler..
Relateret debat
18 sep - 
Håber du har ret
18 sep - 
Lur mig nu ikke den lukker i sollidt plus
18 sep - 
Købt lidt igen, tror stadig den skal over 400 kr. igen

Valby, Denmark, 2018-03-20 14:01 CET (GLOBE NEWSWIRE) --

 

Valby, Denmark, 20 March 2018 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

The proposal to distribute a dividend of 61 % of the net profit for the accounting year 2017, corresponding to DKK 8.00 per share, or a total dividend of DKK 1,592 million, was adopted.

Lars Søren Rasmussen, Lene Skole-Sørensen, Lars Erik Holmqvist and Jeremy Max Levin were re-elected to the Board of Directors. In addition, Jeffrey Berkowitz and Henrik Andersen were elected to the Board of Directors. Jens Jesper Ovesen did not stand for re-election. Immediately after the General Meeting, the Board of Directors elected Lars Søren Rasmussen as Chairman and Lene Skole-Sørensen as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:  

  • Lars Søren Rasmussen (Chairman)

  • Lene Skole-Sørensen (Deputy Chairman)

  • Lars Erik Holmqvist

  • Jeremy Max Levin

  • Jeffrey Berkowitz

  • Henrik Andersen

  • Ludovic Tranholm Otterbein (employee representative)

  • Jørn Møller Mayntzhusen (employee representative)

  • Rikke Kruse Andreasen (employee representative)

 

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Henrik Andersen, Lars Søren Rasmussen and Lars Erik Holmqvist were elected as members of the Audit Committee. Lars Søren Rasmussen and Lene Skole-Sørensen were elected as members of the Remuneration Committee. Jeremy Max Levin, Lene Skole-Sørensen and Jeffrey Berkowitz were elected as members of the Scientific Committee.

The General Meeting approved the remuneration for the Board of Directors for the year 2018.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The proposal to give the Board of Directors authorization until the next annual general meeting to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on NASDAQ Copenhagen A/S at the time of the acquisition.

The Chairman of the General Meeting was authorised to file for registration the resolutions passed at the general meeting with the Danish Business Authority.

No other business was on the agenda at the Annual General Meeting.

At a Board of Directors’ meeting held immediately after the Annual General Meeting the Board of Directors decided to amend Lundbeck’s Articles of Association by deleting certain expired warrant programs and authorizations. The updated Articles of Association can be found at Lundbeck’s web-page: www.Lundbeck.com.

 

The Board of Directors

  

Lundbeck contacts

Investors:

Media:

 

 

Palle Holm Olesen

Mads Kronborg

Vice President, Investor Relations

Senior Director, Corp. Communication

PALO@lundbeck.com

MAVK@lundbeck.com

+45 30 83 24 26

+45 36 43 40 00

 

 

 

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

   

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

 

Vedhæftet fil: UK_PDF.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Alm. Brand og Topdanmark hæves til "køb" af Danske Markets - NY

24-09-2018 10:03:34
Danske Markets hæver anbefalingen af aktierne i de to forsikringsselskaber Alm. Brand og Topdanmark.I begge tilfælde er anbefalingen hævet til "køb" fra tidligere "hold", fremgår det af Bloomberg News. Kursmålet for Topdanmark-aktien er justeret op til 320 kr. fra før 300 kr., mens 12-måneders kursmålet for Alm. Brands aktie er fastholdt på 64 kr. Danske Markets gentager i øvrigt en købsanbefaling..

Aktier/tendens: Mærsk og Coloplast i fokus midt i handelskonflikt

24-09-2018 08:26:39
Coloplast og Mærsk kan komme i rampelyset mandag morgen, hvor de fortsatte handelsstridigheder mellem USA og Kina også vil være et af dagens store samtaleemner efter nye tariffer og en kinesisk afvisning af at deltage i nye handelsforhandlinger.Det tyder også på, at de danske eliteaktier skal en tur ned mandag morgen, hvor markedet igen er præget af den seneste udvikling i handelsstriden mellem US..

Danske: Moody's ser risiko for sænkning af kreditvurderingen - NY

21-09-2018 15:14:23
Moody's Investors Service er gået i gang med at kigge kreditvurderingen af Danske Bank efter i sømmene og forudser, at der er risiko for en nedjustering. Det oplyser ratinginstituttet fredag, hvor udsigten for Danske Banks kreditvurdering er sænket til "negativ" fra "stabil".Ændringen kommer, efter at banken har offentliggjort rapporten om hvidvask i sin estiske filial tidligere på ugen, skriver M..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank-investorer sætter aktien på vippen - citat
2
Danske Bank er millimeter fra at udpege ny topchef - citat
3
Aktier/tendens: Mærsk og Coloplast i fokus midt i handelskonflikt
4
Aktier/middag: Ambu og Danske ryger til bunds i nervøst aktiemarked
5
Rejseselskab nedjusterer og ansætter tidligere Pandora- og Lego-chef

Relaterede aktiekurser

Lundbeck A/S 389,80 2,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. september 2018 15:18:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180919.1 - EUROWEB5 - 2018-09-24 15:18:44 - 2018-09-24 15:18:44 - 1 - Website: OKAY